Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;96(8):e29831.
doi: 10.1002/jmv.29831.

An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge

Huixiong Deng  1 , Yanlei Li  1 , Xuanting He  1 , Haoyang Wang  1 , Shenmiao Wang  1 , Hengyao Zhang  1 , Jiacheng Zhu  1 , Liming Gu  1 , Rui Li  1 , Gefei Wang  1
Affiliations

An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge

Huixiong Deng et al. J Med Virol. 2024 Aug.

Abstract

Coxsackievirus B3 (CVB3) triggers viral myocarditis, with no effective vaccine yet. This fecal-oral transmitted pathogen has prompted interest in mucosal immunization strategies to impede CVB3 spread. We developed a new attenuated vaccine strain, named CVB3(mu). The potential of CVB3(mu) to stimulate mucosal immune protection remains to be elucidated. This study evaluates the attenuation characteristics of CVB3(mu) via a rapid evolution cellular model and RNA sequencing. Its temperature sensitivity and safety were evaluated through in vitro and in vivo experiments. The mucosal immunity protection of CVB3(mu) was assessed via intranasal immunization in Balb/c mice. The results indicate that CVB3(mu) exhibits temperature sensitivity and forms smaller plaques. It sustains fewer genetic mutations and still possesses certain attenuated traits up to the 25th passage, in comparison to CVB3(WT). Intranasal immunization elicited a significant serum neutralizing antibodies, and a substantial sIgA response in nasal washes. In vivo trials revealed CVB3(mu) protection in adult mice and passive protection in suckling mice against lethal CVB3(WT) challenges. In conclusion, CVB3(mu), a live attenuated intranasal vaccine, provides protection involving humoral and mucosal immunity, making it a promising candidate to control CVB3 spread and infection.

Keywords: CVB3; attenuated; intranasal immunization; mucosal immunity; vaccine.

PubMed Disclaimer

References

REFERENCES

    1. Garmaroudi FS, Marchant D, Hendry R, et al. Coxsackievirus B3 replication and pathogenesis. Future Microbiol. 2015;10(4):629‐653. doi:10.2217/fmb.15.5
    1. Han Z, Zhang Y, Huang K, et al. Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect Dis. 2019;19(1):466. doi:10.1186/s12879-019-4107-z
    1. Abedi GR, Watson JT, Nix WA, Oberste MS, Gerber SI. Enterovirus and Parechovirus Surveillance—United States, 2014‐2016. MMWR Morb Mortal Wkly Rep. 2018;67(18):515‐518. doi:10.15585/mmwr.mm6718a2
    1. Yang Q, Yan D, Song Y, et al. Whole‐genome analysis of coxsackievirus B3 reflects its genetic diversity in China and worldwide. Virol J. 2022;19(1):69. doi:10.1186/s12985-022-01796-0
    1. Bouin A, Nguyen Y, Wehbe M, et al. Major persistent 5' terminally deleted coxsackievirus B3 populations in human endomyocardial tissues. Emerging Infect Dis. 2016;22(8):1488‐1490. doi:10.3201/eid2208.160186

MeSH terms

LinkOut - more resources